Quarterly report pursuant to Section 13 or 15(d)

4. Commitments and Contingencies (Details Narrative)

v2.4.0.6
4. Commitments and Contingencies (Details Narrative) (USD $)
 3 Months Ended 9 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2012
Commitments And Contingencies Details Narrative          
Potential Severance of Key Executives $ 1,918,000   $ 1,918,000    
Aggregated Annual Salaries of Key Executives 1,360,000   1,360,000    
Option payment received from AmDerma, recorded as deferred revenue     250,000    
Revenues from Vetericyn & Microcyn sales 883,000 665,000 3,248,000 2,400,000  
Outstanding receivables related to Innovacyn, Inc. 439,000   439,000   290,000
Outstanding accounts receivable due from More Pharma     1,306,000    
Recognized revenue related to the upfront fees of the More Pharma transaction 379,000   566,000    
Expense related to the transaction costs of the More Pharma transaction $ 16,000   $ 24,000